Trevi Therapeutics

clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions. The company was established in 2011 and is headquartered out of New Haven, Connecticut.